Last reviewed · How we verify
TESTOSTERONE PROPIONATE
Testosterone Propionate is a marketed androgenic-anabolic steroid with a well-established presence in the hormone replacement therapy market. Its key strength lies in its long-standing use and familiarity among healthcare providers, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches, which could erode market share and revenue.
At a glance
| Generic name | TESTOSTERONE PROPIONATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
Common side effects
Key clinical trials
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism (PHASE3)
- Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone (PHASE1)
- Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance (PHASE4)
- Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study (PHASE2)
- Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo (PHASE4)
- Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer (PHASE2)
- Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TESTOSTERONE PROPIONATE CI brief — competitive landscape report
- TESTOSTERONE PROPIONATE updates RSS · CI watch RSS